Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?

Opinion
Video

This video segment explores the potential role of KRAS-targeted therapies in the frontline treatment of KRAS-positive metastatic NSCLC, highlighting considerations for specific patient populations and disease characteristics.

MOTM24_CN_NSCLC_Seg10_1L-_1
Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • In your opinion, is there a place for these treatments in the frontline treatment of KRAS+ metastatic NSCLC?
      Related Content